Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.50), $0.08 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $58.3 million versus the consensus estimate of $56.31 million.

Guidance:

ACADIA is updating its 2018 NUPLAZID net sales guidance to be between $220 million and $225 million from a previous range of $210 million to $225 million.

ACADIA is updating its guidance for year end 2018 cash, cash equivalents and investment securities on its balance sheet to be between $160 million to $170 million from a previous range of $155 million to $170 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.